Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis

Thromb Haemost. 2005 Dec;94(6):1341-3. doi: 10.1160/th05-06-1341.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Blood Coagulation Tests
  • Drug Therapy, Combination
  • Fibrinolysis / drug effects*
  • Humans
  • Multiple Myeloma / blood
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Prospective Studies
  • Risk Factors
  • Thalidomide / administration & dosage
  • Thromboembolism / etiology*
  • Venous Thrombosis / etiology*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Thalidomide